Microsoft Technology Licensing, LLC

Immune Biosolutions Inc

Maxime Tremblay

Nicolas Guillaume Delfosse

Michael Edward Beverland

Jean-Francois Larrivee

Simon Gaudreau

Frederic Leduc

Louis-Charles Fortier

Steeve Veronneau

Martin Cloutier

Djorjde Gbric

Jean-François Larrivee

A quantum measurement circuit implements a hypergraph product code (HPG). A syndrome can be extracted from the circuit by preparing a readout qubit of the quantum measurement circuit in a known state, preparing a row-based measurement gadget, and preparing a column-based measurement gadget in the quantum measurement circuit. The row-based measurement gadget entangles the readout qubit with a first subset of the target set of data qubits in a same row of the quantum measurement circuit as the readout qubit, and the column based gadget entangles the readout qubit with a second subset of the target set of data qubits in a same column of the quantum measurement circuit as the readout qubit. The syndrome is extracted by measuring the readout qubit to extract the parity of the target set of data qubits.

Short-depth syndrome extraction circuits in 2D quantum architectures for hypergraph product codes

A disclosed methodology for syndrome extraction in a quantum measurement circuit includes generating a graph representing a code implemented by the quantum measurement circuit. The graph includes bit nodes corresponding to data qubits in the quantum measurement circuit, check nodes corresponding to syndrome qubits in the quantum measurement circuit, and edges between the bit nodes and check nodes that are each associated with a stabilizer measurement provided by the code. The methodology provides for assigning each of the different edges in the graph to a select one of 'G' number of different edge types and performing at least G-number of temporally-separated rounds of qubit operations that each enact concurrent multi-qubit operations on endpoints of a subset of the edges assigned to a same one of the G different edge types.

Short-depth syndrome extraction circuits for Calderbank Shor Steane (CSS) stabilizer codes

It is described a(-) toxins A and/or B as a target for therapy, including passive immunotherapy, and particularly prevention of-intoxication in human or other animals. It is also described a polypeptide comprising a portion of-toxins A and/or B sequence being an epitope for anti-toxins A and/or B antibody. It is also disclosed a method for generating a neutralizing antibody directed against-toxins A and/or B. It is also provided a novel formulation that combines key toxins A and/or B epitope antibodies, located in three key domains of toxins A and/or B, for neutralizing toxins A and/or B, at any stage of toxins A and/or B intoxication related to-infection. The novel formulation of toxins A and/or B epitope antibodies are useful in immunotherapy, for therapeutic and/or prophylactic mediation of-intoxication.

Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof

Growing community of inventors

Sherbrooke, Canada

Maxime Tremblay